CClinicalTrials.gg
TerminatedNCT04066413StardustUpdated Sep 28, 2023

Growth and Tolerance Trial on Infant Formula With HMO

An interventional study of Standard infant formula and Infant formula supplemented with HMO in Healthy Growth, sponsored by FrieslandCampina. Terminated at 1 site in United States. Open to participants aged Up to 1 Month, including healthy volunteers. Per ClinicalTrials.gov, last updated 2023-09-28.

Sponsored by FrieslandCampina · Not applicable, Interventional, and Treatment

Why this study was terminated
Due to recruitment difficulties
Phase
Not applicable
Study type
Interventional
Enrollment
265
Allocation
Randomized
Ages
Up to 1 Month
Sex
All
01

Study summary

The aim of the study is to compare growth of healthy infants fed an infant formula supplemented with a human milk oligosaccharide to that of infants on standard formula.

02

Conditions studied

  • Healthy Growth

Keywords

  • infant formula
  • human milk oligosaccharide
  • HMO
  • growth
03

In context

Lead sponsor

FrieslandCampina is the lead sponsor of 11 studies on the registry; 1 is open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
Up to 1 Month
Sexes eligible
All
Accepts healthy volunteers
Yes

Inclusion criteria

  • Gestational age ≥ 37 weeks
  • Birth weight ≥ 2500 grams
  • No recognized diseases (such as cardiac, pulmonary, gastrointestinal, renal or genetic diseases)
  • Boys and girls
  • Recruited \< 1 month/age
  • Being available for follow up until the age of 4 months
  • Exclusive formula feeding or exclusive breast feeding at time of recruitment

Exclusion criteria

Exclusion Criteria:

  • Gestational age \<37 weeks
  • Birth weight \<2500 grams
  • Severe acquired or congenital diseases, mental or physical disorders
  • Illness at screening/ inclusion
  • Incapability of parents/caregivers to comply with the study protocol
  • Received antibiotics within the first month of life
  • Not tolerating standard cow's milk based infant formula
  • Participation in another clinical trial
  • Maternal illicit drug use during pregnancy or post-partum period
  • Parent/caregiver does not have a cell phone to use for filling out questionnaires
05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Triple (Participant, Investigator, Outcomes assessor)
Enrollment
265 participants (actual)

Study arms

  • No intervention
    Breastfed group

    Non-randomized breastfed reference group

  • Placebo comparator
    Control formula

    Group receiving standard infant formula

    Other: Standard infant formula

  • Active comparator
    Formula with HMO

    Group receiving standard infant formula supplemented with HMO

    Other: Infant formula supplemented with HMO

Interventions

  • OtherStandard infant formula

    Standard infant formula

  • OtherInfant formula supplemented with HMO

    Infant formula supplemented with HMO

06

What researchers measure

Primary outcomes

  1. Growth

    Infant growth measured as body weight gain per day

    Time frame: From enrollment until end of the 3 month-study

Secondary outcomes

  1. Weight

    Infant weight (kg)

    Time frame: Monthly, from enrollment until end of the 3 month-study

  2. Recumbent length

    Infant length (cm and cm/day)

    Time frame: Monthly, from enrollment until end of the 3 month-study

  3. Head circumference

    Head circumference (cm and cm/day)

    Time frame: Monthly, from enrollment until end of the 3 month-study

  4. Anthropometry z-scores

    World Health Organization (WHO) growth standard calculated z-scores for weight, length, weight-for-length and head circumference

    Time frame: Monthly, from enrollment until end of the 3 month-study

  5. Formula tolerance

    Parents are asked to keep a diary on formula intake 3 days prior to each monthly study visit

    Time frame: Monthly, from enrollment until end of the 3 month-study

  6. Gastro-intestinal comfort

    Parents are asked to keep a diary 3 days prior to each monthly study visit including questions on gastro-intestinal symptoms (e.g. cramps, constipation, vomiting) and crying behavior

    Time frame: Monthly, from enrollment until end of the 3 month-study

07

Study locations

1 site
  • Cincinnati Children's Hospital Medical Center
    Cincinnati, Ohio 45229-3026, United States
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Updates

Tracking since Sep 25, 2026
No changes since tracking began. The registry record was last updated on Sep 28, 2023, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT04066413
Lead sponsor
FrieslandCampina
Responsible party
Sponsor
First posted
Aug 26, 2019
Start date
Sep 23, 2019
Primary completion
Jan 26, 2023
Completion
Jan 26, 2023
Last update
Sep 28, 2023

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is terminated, as verified in Sep 2023. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion